Sarepta Therapeutics (SRPT) Other Non Operating Income (2010 - 2026)

Sarepta Therapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income rose 81.64% year-over-year to -$15.3 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 103.44% increase from a year earlier, with the FY2025 full-year figure at -$19.3 million, changed N/A from the prior year.
• Other Non Operating Income advanced to -$15.3 million in Q1 2026 per SRPT's latest filing, from -$157.9 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $387.3 million in Q1 2023 and bottomed at -$157.9 million in Q4 2025.
• The 5-year median for Other Non Operating Income is $5.5 million (2022), against an average of $28.1 million.
• Across the five-year window, Other Non Operating Income plunged 27076.56% in 2022 and jumped 2343.27% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at $5.5 million in 2022, then surged by 6907.42% to $387.3 million in 2023, then plunged by 108.43% to -$32.6 million in 2024, then sank by 383.91% to -$157.9 million in 2025, then soared by 90.34% to -$15.3 million in 2026.
• Per Business Quant, the three latest SRPT Other Non Operating Income figures stand at -$15.3 million (Q1 2026), -$157.9 million (Q4 2025), and $138.6 million (Q3 2025).